What is the price-to-earnings ratio of Oncology Pharma?
The price-earnings ratio of Oncology Pharma is currently 0.
Oncology Pharma P/S 2024
Oncology Pharma P/S
0
Ticker
ONPH
ISIN
US68235J2015
WKN
A2QEWD
As of Sep 29, 2024, Oncology Pharma's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.
The Oncology Pharma P/S history
Oncology Pharma Aktienanalyse
What does Oncology Pharma do?
Oncology Pharma Inc is a global biotechnology company working on the development of therapies and medications against various types of cancer. The company was founded in the USA in 2011 and is headquartered in Boston, Massachusetts. Its business model is based on developing and marketing medications focused on fighting cancer. The company specializes in targeted therapies, immunotherapies, and combination therapies. Oncology Pharma's products have the potential to revolutionize cancer treatment and improve the lives of millions of people worldwide. Oncology Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Oncology Pharma's P/S Ratio
Oncology Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Oncology Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Oncology Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Oncology Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Oncology Pharma stock
How has the price-earnings ratio of Oncology Pharma changed compared to last year?
The price-to-earnings ratio of Oncology Pharma has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Oncology Pharma high compared to other companies?
Yes, the price-to-earnings ratio of Oncology Pharma is high compared to other companies.
How does an increase in the price-earnings ratio of Oncology Pharma affect the company?
An increase in the price-earnings ratio of Oncology Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Oncology Pharma affect the company?
A decrease in the price-earnings ratio of Oncology Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Oncology Pharma?
Some factors that influence the price-earnings ratio of Oncology Pharma are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Oncology Pharma pay?
Over the past 12 months, Oncology Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncology Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of Oncology Pharma?
The current dividend yield of Oncology Pharma is .
When does Oncology Pharma pay dividends?
Oncology Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oncology Pharma?
Oncology Pharma paid dividends every year for the past 0 years.
What is the dividend of Oncology Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oncology Pharma located?
Oncology Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oncology Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oncology Pharma from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.
When did Oncology Pharma pay the last dividend?
The last dividend was paid out on 9/29/2024.
What was the dividend of Oncology Pharma in the year 2023?
In the year 2023, Oncology Pharma distributed 0 USD as dividends.
In which currency does Oncology Pharma pay out the dividend?
The dividends of Oncology Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Oncology Pharma
Our stock analysis for Oncology Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncology Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Oncology Pharma Revenue
- Oncology Pharma Net Income
- Oncology Pharma P/E
- Oncology Pharma P/S
- Oncology Pharma EBIT
- Oncology Pharma Dividend
- Oncology Pharma Stocks
- Oncology Pharma Market capitalization
- Oncology Pharma Debt
- Oncology Pharma Liabilities
- Oncology Pharma Equity
- Oncology Pharma AAQS
- Oncology Pharma Employees
- Oncology Pharma ROE
- Oncology Pharma ROA
- Oncology Pharma ROCE
